Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VBIV

VBI Vaccines (VBIV) Stock Price, News & Analysis

VBI Vaccines logo

About VBI Vaccines Stock (NASDAQ:VBIV)

Key Stats

Today's Range
$0.07
$0.07
50-Day Range
$0.02
$0.79
52-Week Range
$0.06
$1.35
Volume
N/A
Average Volume
3.66 million shs
Market Capitalization
$1.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VBIV Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
See More Headlines

VBIV Stock Analysis - Frequently Asked Questions

VBI Vaccines Inc. (NASDAQ:VBIV) announced its quarterly earnings data on Monday, March, 13th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 525.42% and a negative net margin of 881.79%.

VBI Vaccines shares reverse split on the morning of Wednesday, April 12th 2023.The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Novavax (NVAX).

Company Calendar

Last Earnings
3/13/2023
Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VBIV
CIK
764195
Fax
N/A
Employees
22
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$92.84 million
Net Margins
-881.79%
Pretax Margin
-881.79%
Return on Equity
-525.42%
Return on Assets
-45.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.34
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$9.41 million
Price / Sales
0.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
28,682,000
Free Float
25,713,000
Market Cap
$1.87 million
Optionable
No Data
Beta
2.18

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:VBIV) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners